Clinical trial · no report yet · Phase 3
RADIANT-2
Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
- NCT00412061 ↗
- Completed
- Novartis Pharmaceuticals
- 9 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 6 | |
| Podcasts | 3 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Double-blind Placebo-controlled, Multicenter Phase III Study in Patients With Advanced Carcinoid Tumor Receiving Octreotide Depot and Everolimus 10 mg/Day or Octreotide Depot and Placebo
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Carcinoid Tumor; Malignant Carcinoid Syndrome
- Interventions
- Octreotide; Placebo; Everolimus
- Arms
- Octreotide+ Everolimus · Experimental
- Octreotide+ Placebo · Placebo comparator
- Enrollment
- 429
- Primary outcomes
- Progression Free Survival (PFS) as Per Adjudicated Central Radiology Review
- Sponsor
- Novartis Pharmaceuticals
- Start
- Dec 2006
- Primary completion
- Apr 2010
- Results posted
- Yes
- Registry record
- NCT00412061 · updated Nov 21, 2014
Publications
linked from the registry- Pavel ME, Baudin E, Oberg KE, Hainsworth JD, Voi M, Rouyrre N, Peeters M, Gross DJ, Yao JC. Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. Ann Oncol. 2017 Jul 1;28(7):1569-1575. doi: 10.1093/annonc/mdx193. PubMed 28444114
- Fazio N, Granberg D, Grossman A, Saletan S, Klimovsky J, Panneerselvam A, Wolin EM. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study. Chest. 2013 Apr;143(4):955-962. doi: 10.1378/chest.12-1108. PubMed 23187897
- Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC; RADIANT-2 Study Group. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011 Dec 10;378(9808):2005-2012. doi: 10.1016/S0140-6736(11)61742-X. Epub 2011 Nov 25. PubMed 22119496